Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

A blood test could map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy, according to researchers at Mayo Clinic and Stanford Medicine. The test they developed could help guide treatment decisions across multiple cancer types and treatments.

May 08, 2026

Vol.52 No.18

Clinical Roundup

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

A Mayo Clinic has developed an artificial intelligence model that can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Mayo Clinic pilot study demonstrates safety, feasibility of delivering chemotherapy at home

Findings from a pilot study conducted by Mayo Clinic researchers suggest that chemotherapy can be safely delivered in patients’ homes.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

YOU MAY BE INTERESTED IN

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

Mayo Clinic pilot study demonstrates safety, feasibility of delivering chemotherapy at home

Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login